ArticleMarine drugs2019
Probing Multi-Target Action of Phlorotannins as New Monoamine Oxidase Inhibitors and Dopaminergic Receptor Modulators with the Potential for Treatment of Neuronal Disorders.
Article in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Ultrasonic-assisted extraction, purification, identification, and bioactivity evaluation of phlorotannins from Sargassum fusiforme: A comparative study of RSM and SVM-GA.Ultrasonics sonochemistry · 2026Article
- Neuroproteomic Profiling of the Anxiolytic Potential ofInternational journal of molecular sciences · 2026Article
- Review
- In Vitro Human Monoamine Oxidase Inhibition and Human Dopamine DInternational journal of molecular sciences · 2023Article
- Dopamine and serotonin alterations byNutrition research and practice · 2023Article
- Therapeutic effects of phlorotannins in the treatment of neurodegenerative disorders.Frontiers in molecular neuroscience · 2023Review
- In-Depth Understanding ofMarine drugs · 2022Review
- New Monocyclic Terpenoid Lactones from a Brown AlgaePlants (Basel, Switzerland) · 2022Article
- Natural Products Inhibitors of Monoamine Oxidases-Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma.Molecules (Basel, Switzerland) · 2022Review
- Biological Potential, Gastrointestinal Digestion, Absorption, and Bioavailability of Algae-Derived Compounds with Neuroprotective Activity: A Comprehensive Review.Marine drugs · 2022Review
- Update on GPCR-based targets for the development of novel antidepressants.Molecular psychiatry · 2022Review
- Natural α-Glucosidase and Protein Tyrosine Phosphatase 1B Inhibitors: A Source of Scaffold Molecules for Synthesis of New Multitarget Antidiabetic Drugs.Molecules (Basel, Switzerland) · 2021Review
- Monoamine Oxidase Inhibition by Major Tanshinones fromBiomolecules · 2021Article
- In Vitro and In Silico Characterization of G-Protein Coupled Receptor (GPCR) Targets of Phlorofucofuroeckol-A and Dieckol.Marine drugs · 2021Article
- Neuroprotective Effect of Aurantio-Obtusin, a Putative Vasopressin VInternational journal of molecular sciences · 2021Article
- Polyphenols from Brown Seaweeds (Ochrophyta, Phaeophyceae): Phlorotannins in the Pursuit of Natural Alternatives to Tackle Neurodegeneration.Marine drugs · 2020Review
- Emodin Derivatives as Multi-Target-Directed Ligands Inhibiting Monoamine Oxidase and Antagonizing Vasopressin VACS omega · 2020Article
- Seaweed Phenolics: From Extraction to Applications.Marine drugs · 2020Review
- Neuroprotective Potentials of Marine Algae and Their Bioactive Metabolites: Pharmacological Insights and Therapeutic Advances.Marine drugs · 2020Review
- Establishing GPCR Targets of hMAO Active Anthraquinones fromACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modulation of multiple protein targets with a single compound is essential for the effective treatment of central nervous system disorders. In our previous G protein-coupled receptor (GPCR) cell-based study, a selective human monoamine oxidase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.